Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Feb;84(3):329–334. doi: 10.1054/bjoc.2000.1584

Low interleukin-1α messenger RNA levels predict decreased overall survival time of patients with urinary bladder carcinoma

M Seddighzadeh 1, G Steineck 2, O Jansson 3, P Larsson 4, H Wijkström 5, J Adolfsson 5, N Portwood 1, J Hansson 1, S Linder 1
PMCID: PMC2363735  PMID: 11161396

Abstract

Due to our inability to exactly characterize tumours, many patients with urinary bladder cancer undergo unnecessary surgery or cytostatic therapy. We have here studied the expression of the cytokine interleukin-1α (IL-1α) in 73 human bladder carcinomas in relation to patient survival, and examined possible relationships between IL-1α and urokinase plasminogen activator (uPA) expression. Expression levels of IL-1α and uPA mRNA were determined by RT-PCR using the quantitative TaqMan technique. The levels of IL-1α mRNA expression did not differ significantly between tumours of different grade or stage. Calculation of the overall survival rates showed a decreased overall survival time for patients with low levels of IL-1α mRNA in their tumours (log rank; P = 0.0002, median follow up: 37 months). Low tumoral IL-1α expression predicted decreased survival of patients with poorly differentiated tumours (P< 0.005) and of patients with invasive tumours (P = 0.02). uPA expression was about 4-fold increased in poorly differentiated tumours. High levels of uPA mRNA were associated with decreased overall survival times (log rank; P = 0.032, n = 60). We conclude that IL-1α is important for bladder cancer biology, and that measurements of this cytokine may be useful in pre-treatment characterization of urinary bladder cancer. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: urinary bladder cancer, interleukin-1, urokinase

Full Text

The Full Text of this article is available as a PDF (195.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergkvist A., Ljungqvist A., Moberger G. Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years. Acta Chir Scand. 1965 Oct;130(4):371–378. [PubMed] [Google Scholar]
  2. Bhat-Nakshatri P., Newton T. R., Goulet R., Jr, Nakshatri H. NF-kappaB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1alpha. Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6971–6976. doi: 10.1073/pnas.95.12.6971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brinckerhoff C. E., Sirum-Connolly K. L., Karmilowicz M. J., Auble D. T. Expression of stromelysin and stromelysin-2 in rabbit and human fibroblasts. Matrix Suppl. 1992;1:165–175. [PubMed] [Google Scholar]
  4. Burrows F. J., Haskard D. O., Hart I. R., Marshall J. F., Selkirk S., Poole S., Thorpe P. E. Influence of tumor-derived interleukin 1 on melanoma-endothelial cell interactions in vitro. Cancer Res. 1991 Sep 15;51(18):4768–4775. [PubMed] [Google Scholar]
  5. Böhle A. BCG's mechanism of action - increasing our understanding. For the EBIN Group. Eur Urol. 2000;37 (Suppl 1):1–8. doi: 10.1159/000052375. [DOI] [PubMed] [Google Scholar]
  6. Conti P., Reale M., Nicolai M., Barbacane R. C., Placido F. C., Iantorno R., Tenaglia R. Bacillus Calmette-Guérin potentiates monocyte responses to lipopolysaccharide-induced tumor necrosis factor and interleukin-1, but not interleukin-6 in bladder cancer patients. Cancer Immunol Immunother. 1994 Jun;38(6):365–371. doi: 10.1007/BF01517205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dinarello C. A. Biologic basis for interleukin-1 in disease. Blood. 1996 Mar 15;87(6):2095–2147. [PubMed] [Google Scholar]
  8. Dinarello C. A. Interleukin-1. Cytokine Growth Factor Rev. 1997 Dec;8(4):253–265. doi: 10.1016/s1359-6101(97)00023-3. [DOI] [PubMed] [Google Scholar]
  9. Douvdevani A., Huleihel M., Zöller M., Segal S., Apte R. N. Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer. Int J Cancer. 1992 Jul 9;51(5):822–830. doi: 10.1002/ijc.2910510526. [DOI] [PubMed] [Google Scholar]
  10. Engel G., Heselmeyer K., Auer G., Bäckdahl M., Eriksson E., Linder S. Correlation between stromelysin-3 mRNA level and outcome of human breast cancer. Int J Cancer. 1994 Sep 15;58(6):830–835. doi: 10.1002/ijc.2910580614. [DOI] [PubMed] [Google Scholar]
  11. Epstein J. I., Amin M. B., Reuter V. R., Mostofi F. K. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998 Dec;22(12):1435–1448. doi: 10.1097/00000478-199812000-00001. [DOI] [PubMed] [Google Scholar]
  12. Flamm J. The value of tumor-associated tissue inflammatory reaction in primary superficial bladder cancer. Urol Res. 1990;18(2):113–117. doi: 10.1007/BF00302470. [DOI] [PubMed] [Google Scholar]
  13. Hall R. R., Prout G. R. Staging of bladder cancer: is the tumor, node, metastasis system adequate? Semin Oncol. 1990 Oct;17(5):517–523. [PubMed] [Google Scholar]
  14. Hasui Y., Marutsuka K., Suzumiya J., Kitada S., Osada Y., Sumiyoshi A. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer. 1992 Apr 1;50(6):871–873. doi: 10.1002/ijc.2910500607. [DOI] [PubMed] [Google Scholar]
  15. Hayashi O., Akashi M., Fujime M., Hanazawa K., Kitagawa R. Detection of interleukin-1 activity in human bladder cancer cell lines. J Urol. 1994 Mar;151(3):750–753. doi: 10.1016/s0022-5347(17)35080-2. [DOI] [PubMed] [Google Scholar]
  16. Heid C. A., Stevens J., Livak K. J., Williams P. M. Real time quantitative PCR. Genome Res. 1996 Oct;6(10):986–994. doi: 10.1101/gr.6.10.986. [DOI] [PubMed] [Google Scholar]
  17. Hellsten S., Steineck G. Bladder cancer in Sweden. Med Oncol. 1997 Sep-Dec;14(3-4):141–143. doi: 10.1007/BF02989641. [DOI] [PubMed] [Google Scholar]
  18. Janik J. E., Miller L. L., Longo D. L., Powers G. C., Urba W. J., Kopp W. C., Gause B. L., Curti B. D., Fenton R. G., Oppenheim J. J. Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma. J Natl Cancer Inst. 1996 Jan 3;88(1):44–49. doi: 10.1093/jnci/88.1.44. [DOI] [PubMed] [Google Scholar]
  19. Jin L., Yuan R. Q., Fuchs A., Yao Y., Joseph A., Schwall R., Schnitt S. J., Guida A., Hastings H. M., Andres J. Expression of interleukin-1beta in human breast carcinoma. Cancer. 1997 Aug 1;80(3):421–434. doi: 10.1002/(sici)1097-0142(19970801)80:3<421::aid-cncr10>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  20. Lamm D. L. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol. 1985 Jul;134(1):40–47. doi: 10.1016/s0022-5347(17)46972-2. [DOI] [PubMed] [Google Scholar]
  21. Leizer T., Clarris B. J., Ash P. E., van Damme J., Saklatvala J., Hamilton J. A. Interleukin-1 beta and interleukin-1 alpha stimulate the plasminogen activator activity and prostaglandin E2 levels of human synovial cells. Arthritis Rheum. 1987 May;30(5):562–566. doi: 10.1002/art.1780300511. [DOI] [PubMed] [Google Scholar]
  22. Linder C., Byström P., Engel G., Auer G., Aspenblad U., Strander H., Linder S. Correlation between basic fibroblast growth factor immunostaining of stromal cells and stromelysin-3 mRNA expression in human breast carcinoma. Br J Cancer. 1998 Mar;77(6):941–945. doi: 10.1038/bjc.1998.155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Michel J. B., Quertermous T. Modulation of mRNA levels for urinary- and tissue-type plasminogen activator and plasminogen activator inhibitors 1 and 2 in human fibroblasts by interleukin 1. J Immunol. 1989 Aug 1;143(3):890–895. [PubMed] [Google Scholar]
  24. Norioka K., Hara M., Kitani A., Hirose T., Hirose W., Harigai M., Suzuki K., Kawakami M., Tabata H., Kawagoe M. Inhibitory effect of human recombinant interleukin-1 alpha and beta on growth of human vascular endothelial cells. Biochem Biophys Res Commun. 1987 Jun 15;145(2):969–975. doi: 10.1016/0006-291x(87)91060-6. [DOI] [PubMed] [Google Scholar]
  25. Okada A., Bellocq J. P., Rouyer N., Chenard M. P., Rio M. C., Chambon P., Basset P. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2730–2734. doi: 10.1073/pnas.92.7.2730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Onozaki K., Matsushima K., Aggarwal B. B., Oppenheim J. J. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol. 1985 Dec;135(6):3962–3968. [PubMed] [Google Scholar]
  27. Pyke C., Kristensen P., Ralfkiaer E., Grøndahl-Hansen J., Eriksen J., Blasi F., Danø K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol. 1991 May;138(5):1059–1067. [PMC free article] [PubMed] [Google Scholar]
  28. Shipley W. U., Winter K. A., Kaufman D. S., Lee W. R., Heney N. M., Tester W. R., Donnelly B. J., Venner P. M., Perez C. A., Murray K. J. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998 Nov;16(11):3576–3583. doi: 10.1200/JCO.1998.16.11.3576. [DOI] [PubMed] [Google Scholar]
  29. Sieuwerts A. M., Klijn J. G., Henzen-Logmans S. C., Foekens J. A. Cytokine-regulated urokinase-type-plasminogen-activator (uPA) production by human breast fibroblasts in vitro. Breast Cancer Res Treat. 1999 May;55(1):9–20. doi: 10.1023/a:1006190729866. [DOI] [PubMed] [Google Scholar]
  30. Stein J. P., Ginsberg D. A., Grossfeld G. D., Chatterjee S. J., Esrig D., Dickinson M. G., Groshen S., Taylor C. R., Jones P. A., Skinner D. G. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst. 1998 Jul 15;90(14):1072–1079. doi: 10.1093/jnci/90.14.1072. [DOI] [PubMed] [Google Scholar]
  31. Têtu B., Brisson J., Côté C., Brisson S., Potvin D., Roberge N. Prognostic significance of cathepsin-D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer. 1993 Sep 30;55(3):429–435. doi: 10.1002/ijc.2910550318. [DOI] [PubMed] [Google Scholar]
  32. Visscher D. W., DeMattia F., Ottosen S., Sarkar F. H., Crissman J. D. Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma. Mod Pathol. 1995 Aug;8(6):665–670. [PubMed] [Google Scholar]
  33. Voronov E., Weinstein Y., Benharroch D., Cagnano E., Ofir R., Dobkin M., White R. M., Zoller M., Barak V., Segal S. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression. Cancer Res. 1999 Mar 1;59(5):1029–1035. [PubMed] [Google Scholar]
  34. Wolf C., Rouyer N., Lutz Y., Adida C., Loriot M., Bellocq J. P., Chambon P., Basset P. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1843–1847. doi: 10.1073/pnas.90.5.1843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Worth L. L., Jaffe N., Benjamin R. S., Papadopoulos N. E., Patel S., Raymond A. K., Jia S. F., Rodriguez C., Gano J., Gianan M. A. Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma. Clin Cancer Res. 1997 Oct;3(10):1721–1729. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES